Non-Invasive versus Invasive Samples for Zika Virus Surveillance: A Comparative Study in New Caledonia and French Guiana in 2015–2016

Marie-Alice Fraiture 1, Wim Coucke 2, Morgane Pol 3, Dominique Rousset 4, Ann-Claire Gourinat 3,‡, Antoine Biron 3,‡, Sylvia Broeders 1,2, Els Vandermassen 1, Myrielle Dupont-Rouzeyrol 3,‡, and Nancy H. C. Roosens 1,‡,†

Transversal & Applied Genomics (TAG), Sciensano, rue Juliette Wytsman 14, 1050 Brussels, Belgium; marie-alice.fraiture@sciensano.be (M.-A.F.); sylvia.broeders@sciensano.be (S.B.); els.vandermassen@sciensano.be (E.V.)
2 Quality of Laboratories, Sciensano, rue Juliette Wytsman 14, 1050 Brussels, Belgium; wim.coucke@sciensano.be
3 URE Dengue et Arboviroses, Institut Pasteur de New Caledonia, 11 avenue Paul Doumer, BP 61, CEDEX, 98845 Noumea, New Caledonia; mpol@pasteur.nc (M.P.); ann-claire.gourinat@cht.nc (A.-C.G.); antoine.biron@cht.nc (A.B.); mdupont@pasteur.nc (M.D.-R.)
4 Laboratoire de Virologie CNR Arbovirus, Institut Pasteur de la Guyane, 23 avenue Pasteur, BP 6010, CEDEX, 97306 Cayenne, French Guiana; drousset@pasteur-cayenne.fr
* Correspondence: nancy.roosens@sciensano.be; Tel.: +32-(0)-2-642-52-58
† Current address: Laboratoire de Microbiologie, Centre Hospitalier Territorial Gaston Bourret, 7 avenue Paul Doumer, BP 61, CEDEX, 98845 Noumea, New Caledonia.
‡ Equal contribution.

Abstract: Zika virus, an arbovirus responsible for major outbreaks, can cause serious health issues, such as neurological diseases. In the present study, different types of samples (serum, saliva, and urine), collected in 2015–2016 in New Caledonia and French Guiana from 53 patients presenting symptoms and clinical signs triggered by arbovirus infections, were analyzed using a recently developed, and in-house validated, 4-plex RT-qPCR TaqMan method for simultaneous detection and discrimination of the Zika and Chikungunya viruses. Subsequently, statistical analyses were performed in order to potentially establish recommendations regarding the choice of samples type to use for an efficient and early stage Zika infection diagnosis. On this basis, the use of only urine samples presented the highest probability to detect viral RNA from Zika virus. Moreover, such a probability was improved using both urine and saliva samples. Consequently, the added value of non-invasive samples, associated with a higher acceptance level for collection among patients, instead of serum samples, for the detection of Zika infections was illustrated.

Keywords: Zika virus; diagnostic; RT-qPCR; serum; urine and saliva samples; public health concern
as well as from mother to fetus via the placenta. In infected humans, ZIKV presence was reported, for example, in blood, saliva, urine, semen, breast milk, nasopharyngeal secretion, cerebrospinal fluid, brain tissue, umbilical cord, amniotic fluid, and placenta [1,2,6,8–11]. The majority of infected patients present no specific clinical features. Indeed, only around 20–25% of them have symptoms and clinical signs, such as headache, fever, rash, conjunctivitis, myalgia, and arthralgia/arthritis, which are usually resolved in 7 days. However, even if the symptoms and clinical signs are generally benign, such infections can cause serious health issues, including fetus malformations, brain defects in newborns, pregnancy problems, Guillain-Barré syndrome, and other neurological and autoimmune complications [1,6,8–11]. Consequently, the World Health Organization (WHO) raised a “Public Health Emergency of International Concern” regarding this emerging pathogen [1–4].

The clinical diagnosis of ZIKV infections is challenging due to frequent asymptomatic infections, as well as the similarity of the clinical signs and symptoms with other arbovirus infections, such as Dengue virus and Chikungunya virus (CHIKV). To determine ZIKV infection, laboratory analyses therefore need to be performed. Among the laboratory techniques, serological and molecular approaches exist and present both advantages and drawbacks. Serological approaches have widely been used; however, such techniques are less sensitive for early stage diagnosis (first days after infection), which is essential to quickly identify the causative pathogen of an emerging epidemic as it markedly increases the chance of success for any countermeasures to constrain the disease. Therefore, to overcome these crucial issues, molecular approaches targeting nucleic acids of interest, such as the reverse transcription real-time polymerase chain reaction (RT-qPCR), are generally privileged [4,8,12–14]. These analyses are usually performed by diagnostic laboratories using serum samples; however, the collection of serum samples does not represent the simplest strategy for massive implementation because it requires medical infrastructure and healthcare teams. In addition, the collection of blood samples can be difficult for application for an entire population, such as with neonates, young children, the elderly, hemophiliacs, and refractory patients, especially if their symptoms and clinical signs are moderate. In this context, the possible use of non-invasive samples (i.e., urine and saliva) presenting a higher acceptance level for collection has recently been investigated. On this basis, the detection of Zika viral RNA in such non-invasive samples from infected patients was successfully demonstrated. In addition, the use of urine samples offered a broader detection window compared to the use of saliva and serum samples [2,4,8,9,14–26].

In the present study, the potential added-value of non-invasive samples (urine and saliva) in comparison to classical serum samples was assessed for ZIKV in terms of early diagnostics and survey. To this end, a large set of urine, saliva, and serum samples was collected in 2015–2016 in New Caledonia and French Guiana from 53 patients presenting symptoms and clinical signs associated with arbovirus infections. All the samples were tested using a recently developed and in-house validated 4-plex RT-qPCR TaqMan method for simultaneously detecting and discriminating ZIKV and CHIKV, which often co-circulate in the same geographical areas and for which the number of co-infection cases is more and more reported [14,27–30]. The generated results were then analyzed statistically in order to highlight the strengths and weaknesses of the tested samples to support diagnostic laboratories.

2. Materials and Methods

2.1. Sample Collection and RNA Extraction

The presented study, including publication of data related to arbovirus infection, was approved by the Comité Consultatif d’Ethique de Nouvelle-Caledonie (February 2015) and by the Comité de Protection des Personnes Ile de France I (March 2015-13851 and January 2018-14793). Human biological samples used in this study were obtained from patients after written informed consent. All samples were collected based on an ethical agreement (n° 2015-mars-13851 and January 2018-14793). Serum, urine, and saliva samples were collected in 2015–2016 from 47 patients from New Caledonia and 6 patients from
French Guiana. These patients presented symptoms and clinical signs associated with arbovirus infections, including ZIKV (Table 1 and Table S1). For thirteen patients (NC-19, NC-23, NC-26, NC-37, NC-40, NC-41, NC-44, NC-46, NC-47, GY-1, GY-4, GY-6, and GY-8), a second sample test was carried out (Table 1 and Table S1). For each patient number, the A and B labels are, respectively, associated to indicate the first and second sample tests. The number of days since onset of symptoms and clinical signs was recorded for each sample. For each sample, the corresponding number of days since onset of symptoms and clinical signs is indicated. For each patient number, the A and B labels are associated to respectively indicate the first sample test and the second sample test. All Cq values above 38 are considered as negative (not detected) and are represented by the symbol “-”. Each Cq value is the average of a duplicate (standard deviation means of 0.5). In the patient number, the symbols NC and GY, corresponding, respectively, to New Caledonia and French Guiana, indicate the sampling areas.

| Patient Number | Days Since Onset of Symptoms/Clinical Signs | SERUM | URINE | SALIVA |
|----------------|--------------------------------------------|-------|-------|--------|
|                |                                            | ZIKV (a) | ZIKV (b) | ZIKV (a) | ZIKV (b) | ZIKV (a) | ZIKV (b) |
| NC-1A          | 3                                          | 34.9 | 37.4 | - | - | 31.4 | 32.8 |
| NC-2A          | 4                                          | 37.6 | - | - | - | - | - |
| NC-3A          | 4                                          | 35.7 | - | 31.4 | 35.1 | 28.4 | 29.8 |
| NC-4A          | 3                                          | - | - | 30.7 | 33.4 | 32.6 | 32.6 |
| NC-8A          | 3                                          | - | - | 25.2 | 28.3 | - | - |
| NC-9A          | 3                                          | 35.7 | - | 33.0 | 36.2 | 30.9 | 32.3 |
| NC-10A         | 5                                          | - | - | 23.8 | 26 | 37.6 | |
| NC-11A         | 5                                          | - | - | 34.1 | 36.6 | - | - |
| NC-12A         | 1                                          | 35.9 | - | 25.8 | 28.9 | 29.8 | 31.1 |
| NC-13A         | 2                                          | 33.8 | 37 | 34.4 | 35.8 | 31.3 | 34.3 |
| NC-14A         | 2                                          | - | - | 28.2 | 29.2 | 30.7 | 31.7 |
| NC-15A         | 4                                          | - | - | 32.0 | 33.7 | 37.6 | - |
| NC-17A         | 2                                          | - | - | 32.8 | 35.6 | 36.5 | - |
| NC-19A         | 1                                          | - | - | 29.7 | 30.6 | 28.3 | 29.4 |
| NC-19B         | 2                                          | - | - | 30.0 | 31.40 | 32.2 | 33.8 |
| NC-21A         | 1                                          | 31.2 | 34.7 | 37.2 | - | 29 | 31.4 |
| NC-23A         | 2                                          | - | - | 31.0 | 33.9 | 30.4 | 32.3 |
| NC-23B         | 6                                          | - | - | 30.9 | 32.9 | 37.7 | - |
| NC-26A         | 2                                          | 35.8 | - | 37.0 | - | 38 | - |
| NC-26B         | 6                                          | 37.4 | - | 37.9 | - | - | - |
| GY-1A          | 2                                          | 33.9 | 34.2 | - | - | - | - |
| GY-1B          | 3                                          | - | - | 32.0 | 32.4 | 36.7 | 37.6 |
| GY-4A          | 3                                          | - | - | 37.8 | 37.1 | - | - |
| GY-5A          | 4                                          | - | - | - | - | 32.2 | 33.2 |
| GY-6A          | 1                                          | - | - | 31.3 | 31.9 | - | - |
| GY-8A          | 6                                          | - | - | 34.2 | 34.5 | - | - |

For each patient, the serum, urine, and saliva samples were tested using a 4-plex targeting CHIKV via the CHIKV (a) and CHIKV (b) methods, and ZIKV via the ZIKV (a) and ZIKV (b) methods. Only results associated with patients with a positive signal are presented. For each sample, the corresponding number of days since onset of symptoms and clinical signs is indicated. For each patient number, the A and B labels are associated to respectively indicate the first sample test and the second sample test. All Cq values above 38 are considered as negative (not detected) and are represented by the symbol “-”. Each Cq value is the average of a duplicate (standard deviation means of 0.5). In the patient number, the symbols NC and GY, corresponding, respectively, to New Caledonia and French Guiana, indicate the sampling areas.
RNA was extracted using the MagNA Pure LC Total Nucleic Acid Isolation Kit (Roche, Indianapolis, IN, USA), for samples from New Caledonia patients, or the QiAamp Viral RNA mini Kit (Qiagen, Kista, Sweden), for samples from French Guiana patients, according to the manufacturer’s instructions. RNA extraction was performed in 2016–2017.

Reference RNA for ZIKV (AMPLIRUN® ZIKA VIRUS RNA CONTROL, VIRCELL®) and CHIKV (AMPLIRUN® CHIKUNGUNYA VIRUS RNA CONTROL, VIRCELL®) were obtained from Labconsult (Schaerbeek, Belgium).

2.2. One Step RT-qPCR

All RT-qPCR assays were carried out on a CFX96 Touch™ (BIO-RAD, Hercules, CA, USA) system using the SuperScript® III Platinum® One-Step RT-qPCR Kit (Invitrogen, Waltham, MA, USA) according to the manufacturers’ instructions. All samples were tested using a 4-plex RT-qPCR targeting both CHIKV, via the CHIKV (a) and CHIKV (b) methods, and ZIKV, via the ZIKV (a) and ZIKV (b) methods (Table 1 and Table S2) [14]. This 4-plex RT-qPCR, previously developed and validated by Broeders et al. (2020), uses two independent target sequences for each virus, improving the reliability of the assay, such as in the case of mutations in one of the target sequences. This 4-plex was also assessed as specific and sensitive (as low as 5–100 cp) [14]. One reference RNA for CHIKV and one for ZIKV were used as positive control [14]. In each PCR reaction, 5 µL of RNA that was extracted from symptomatic patient samples were tested. Each PCR assay was tested in duplicated and the average Cq is indicated in Table 1. The RT-qPCR program consisted of the following successive steps: (i) cDNA synthesis for 15 min at 50 ºC; (ii) initial DNA polymerase activation for 2 min at 95 ºC; (iii) and 45 amplification cycles for 15 s at 95 ºC (denaturation) and for 30 s at 60 ºC (annealing and extension). All reactions were set up on ice and water was used as the no-template control [14]. All signals with a Cq value greater than 38 were considered negative. RT-qPCR assays were performed in 2017–2018.

2.3. Statistical Analysis

2.3.1. Probability of Detection

Based on the Cq values indicated in Table 1, the number of positive and negative samples per kind of sample (serum, urine, and saliva) was used to determine the probability of detecting ZIKV (Figure 1 and Table S3). The significance of this probability using each kind of sample is represented via the p-value (Figure 1B and Table S3). This analysis was performed using S-plus (version 8.0, TIBCO Software Inc, Carlsbad, CA, USA) for Linux, a generalized linear model for binary data. A logit link was fit using the method as a fixed factor and the patient as a random factor. The comparison between the two ZIKV methods were corrected for simultaneous hypothesis testing, according to Sidak.

2.3.2. Signal Precocity

Based on the data in Table 1, the Cq values were compared between samples (urine, saliva, and serum) per patient when both compared samples presented a positive signal (Cq value ≤ 38). For each compared sample, the Cq value from the ZIKV (a) method, indicated in Table 1, was taken into account to calculate the Cq value difference on which the p-value was determined (Table 2). This analysis was performed using a Studentized t-test followed by a correction for simultaneous hypothesis testing, according to Sidak. On this basis, the significance of the signal precocity between the compared samples was assessed (Table 2).
Figure 1. Impact of the samples on the probability to detect ZIKV. (A) Probability of detection (%) of ZIKV in serum, urine and/or saliva samples according to days since onset of symptoms and clinical signs (going from 1 to 25) (Table S3). Serum (black line), urine (blue line), saliva (red line), and urine and/or saliva samples (green line); (B) the significance of the difference between the curves in (A) is indicated by the \( p \)-value. The \( p \)-values in bold are considered as significant (<0.05). The significant sample comparisons are highlighted in grey.

| Compared Samples   | \( p \)-Value |
|--------------------|---------------|
| Saliva Serum       | 0.1334        |
| Saliva Urine       | 0.1107        |
| Saliva Urine and Saliva | 0.0103 |
| Serum Urine        | 0.0002        |
| Serum Urine and Saliva | 0.0001 |
| Urine Urine and Saliva | 0.8229 |
Table 2. Difference in the RT-qPCR signals observed between the serum, urine, and saliva samples. Cq value difference is based on the Cq value from the ZIKV (a) method indicated in Table 1 for each compared sample that were both presenting a positive signal (Cq value ≤ 38). *p*-value in bold is considered significant (<0.05).

| Compared Samples | Cq Value Difference | *p*-Value |
|------------------|--------------------|-----------|
| Serum-Saliva     | −4.4               | 0.0095    |
| Serum-Urine      | −1.3               | 0.8998    |
| Saliva-Urine     | −1.8               | 0.4974    |

3. Results and Discussions

Serum, urine, and saliva samples were collected in 2015–2016 in New Caledonia and French Guiana from 53 patients presenting symptoms and clinical signs associated with arbovirus infections, including mainly fever, myalgia, arthralgia, cephalgia, nausea, retro-orbital pain, and skin rash (Table S1). This large set of 193 samples was analyzed for the potential presence of viral RNA of CHIKV and ZIKV. To this end, a 4-plex RT-qPCR targeting both CHIKV, via the CHIKV (a) and CHIKV (b) methods, and ZIKV, via the ZIKV (a) and ZIKV (b) methods, previously developed and assessed as specific and sensitive by Broeders et al. (2020), was applied (Table 1 and Table S2) [14]. Given that this 4-plex RT-qPCR included two methods for each targeted virus, the detection of these viruses was confirmed when at least one of the corresponding method presented a positive signal. Moreover, a patient was considered as infected when at least a positive signal was observed for either in the serum, urine, or saliva samples.

Among the 53 tested patients, none of them presented viral RNA from CHIKV while viral RNA from ZIKV was observed in 22 patients (Table 1). Such observations are consistent with the fact that, in contrast to CHIKV, ZIKV was one of the most circulating arboviruses during the sampling period [32,33]. For the 22 patients infected with ZIKV, 10 serum, 22 urine, and 18 saliva samples showed a positive signal for viral RNA from ZIKV, suggesting the potential capacity of non-invasive samples to cover a larger number of infected cases than invasive samples. In order to investigate such a hypothesis, statistical tests were performed using the generated RT-qPCR results (Figure 1 and Table S3). On this basis, the relevance of using serum, urine, and/or saliva samples was assessed as follow.

First, the probability of detecting viral RNA from ZIKV was determined for each individual type of sample used (serum, urine, or saliva), regardless the day of declaration of symptoms and clinical signs (Figure 1A). The urine samples presented the highest probability of detection in comparison to the serum and saliva samples. This probability was calculated as being significantly higher for the urine samples than for the serum samples (Figure 1B). Interestingly, the exclusive use of serum samples, which is commonly done in arbovirus diagnostic laboratories [8,17], gave the lowest probability of detection. On this basis, the use of urine samples to diagnose ZIKV, which represented the most appropriate individual test, is strongly advised. Such results are supported by recent studies in which similar recommendations were also made [4,9,17,21–23,34–36].

Second, the probability of detecting viral RNA from ZIKV was assessed using combinations of different types of samples (serum, urine, and/or saliva), regardless of the number of days of declaration of symptoms and clinical signs (Figure 1A). In comparison with the individual use of each type of sample (serum, urine, or saliva), the probability of detection was increased by combining the analyses of the urine and saliva samples, highlighting the added value of non-invasive samples in terms of detection. The probability of detection associated with the combination of urine and saliva samples was also determined as significantly higher than using only the serum or saliva samples (Figure 1B). The use of both the urine and saliva samples, which represented the most appropriate combined test, is thus strongly advised.

Finally, the potential benefit of using certain types of samples to detect ZIKV infections at an early stage was investigated. To this end, the signal precocity, based on the observed
Cq values indicated in Table 1, for each type of sample (serum, urine, or saliva) used individually, was analyzed (Table 2). On this basis, in comparison with the serum samples, the saliva samples presented a positive signal and ZIKV infection was significantly more precocious. However, between the urine and saliva samples as well as between the urine and serum samples, no significant difference was observed in terms of signal precocity.

According to all these results, the present comparative study supports the use of non-invasive samples to detect ZIKV infections. Indeed, compared to serum samples, non-invasive samples offered a higher probability of detection and the saliva samples presented a particular item of interest to target such infection at an early stage. As a perspective, the use of a larger number of samples and patients could be interesting in order to support such data.

4. Conclusions

Based on the present study, the use of one or a combination of non-invasive samples instead of serum samples is highly recommended for the detection of viral RNA from ZIKV at early stage. Indeed, the use of urine samples, as well as the use of both urine and saliva samples, were highlighted as being the most appropriate tests in this study. In addition to their better acceptance for collection among patients, non-invasive samples can easily be collected without any medical background. This can be important in the case of outbreaks, as this would allow supporting overworked healthcare teams. Non-invasive samples are also ideal for either at-home collection kits or self-testing kits, as can be currently observed in the context of the COVID-19 crisis. Given the obvious added value of using non-invasive samples in diagnostics, at the logistic level, as well as in the improvement of diagnostic accuracy, the comparison approach proposed in this study could systematically be applied for all viral infections (e.g., Dengue virus). On this basis, the type(s) of samples being the best compromise for an efficient diagnostic and outbreak surveillance could be determined.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/microorganisms9061312/s1, Table S1: Summary of symptoms and clinical signs related to patient samples; Table S2: Oligonucleotides used in 4-plex RT-qPCR targeting both CHIKV and ZIKV; Table S3: Detection percentage of ZIKV in serum, urine, and/or saliva samples according to the number of days since onset of symptoms and clinical signs.

Author Contributions: M.P., A.-C.G., A.B. collected samples and extracted RNA. M.-A.F. and E.V. performed RT-qPCR experiments. M.-A.F. analyzed data and drafted the manuscript. W.C. performed the statistical analysis. N.H.C.R. helped to design the study and to draft the manuscript. M.-A.F., W.C., M.P., D.R., A.-C.G., A.B., S.B., E.V., M.D.-R. and N.H.C.R. read and approved the final manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This study was financed by “International Network Institut Pasteur” thought the project “Evaluation of the use of non-invasive tests for early screening and survey of arboviruses (Arbo-VIRTUESS)” (ACIP-2014-053).

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board (or Ethics Committee) of the Comité Consultatif d’Ethique de Nouvelle-Calédonie (February 2015) and by the Comité de Pro-tection des Personnes Ile de France I (March 2015-13851 and January 2018-14793).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: Not applicable.

Acknowledgments: The authors would like to thank Centre de Recherche Translationnelle (Institut Pasteur) for their help in the ethical procedures. The authors would like also to thank Julie Peter for her participation.

Conflicts of Interest: The authors declare no conflict of interest.
References

1. Musso, D.; Gubler, D.J. Zika virus. *Clin. Microbiol. Rev.* 2016, 29, 487–524. [CrossRef]

2. Sharma, S.; Tandel, K.; Dash, P.K.; Parida, M. Zika virus: A public health threat. *J. Med. Virol.* 2017, 89, 1693–1699. [CrossRef]

3. Chan, J.F.; Yip, C.C.; Tee, K.M.; Zhu, Z.; Tsang, J.O.; Chik, K.K.; Tsang, T.G.; Chan, C.C.; Poon, V.K.; Sridhar, S.; et al. Improved detection of Zika virus RNA in human and animal specimens by a novel, highly sensitive and specific real-time RT-PCR assay targeting the 5’-untranslated region of Zika virus. *Trop. Med. Int. Health* 2017, 22, 594–603. [CrossRef]

4. Lamb, L.E.; Bartolone, S.N.; Tree, M.O.; Conway, M.J.; Rossignol, J.; Smith, C.P.; Chancellor, C.B. Rapid Detection of Zika Virus in Urine Samples and Infected Mosquitoes by Reverse Transcription-Loop-Mediated Isothermal Amplification. *Sci. Rep.* 2018, 8, 3803. [CrossRef]

5. Barzon, L.; Percivalle, E.; Pacentzi, M.; Rovida, F.; Zavattoni, M.; Del Bravo, P.; Cattelan, A.M.; Palù, G.; Baldanti, F. Virus and Antibody Dynamics in Travelers with Acute Zika Virus Infection. *Clin. Infect. Dis.* 2018, 66, 1173–1180. [CrossRef]

6. Kazmi, S.S.; Ali, W.; Bibi, N.; Nouroz, F. A review on Zika virus outbreak, epidemiology, transmission and infection dynamics. *J. Biol. Res.* 2020, 27, 5. [CrossRef] [PubMed]

7. Huits, R.; Van Den Bossche, D.; Eggermont, K.; Lotgering, E.; Feyens, A.M.; Potters, I.; Jacobs, J.; Van Esbroeck, M.; Cnops, L.; et al. Zika virus RNA detection in urine samples and infected mosquitoes by reverse transcription-quantitative polymerase chain reaction-based assay for broad coverage detection of African and Asian Zika virus lineages. *Virolog. Sin.* 2017, 32, 199–206. [CrossRef]

8. Singh, R.K.; Dhama, K.; Karthik, K.; Tiwari, R.; Khandia, R.; Munjal, A.; Iqbal, H.M.N.; Malik, Y.S.; Bueno-Mari, R. Advances in Diagnosis, Surveillance, and Monitoring of Zika Virus: An Update. *Front. Microbiol.* 2018, 8, 2677. [CrossRef]

9. Ölschläger, S.; Enfissi, A.; Kar, K.M.; Kazanji, M.; Rousset, D. Diagnostic Validation of the RealStar® Zika Virus Reverse Transcription Polymerase Chain Reaction Kit for Detection of Zika Virus RNA in Urine and Serum Specimens. *Am. J. Trop. Med. Hyg.* 2017, 97, 1070–1071. [CrossRef] [PubMed]

10. Simon, O.; Acket, B.; Forfait, C.; Girault, D.; Gourinat, A.C.; Million, P.; Bréard, M.; Vanhomwegen, J.; Billot, S.; Biron, A.; et al. Zika virus outbreak in New Caledonia and GuillaumBarre syndrome: A case-control study. *J. Neurovirol.* 2018, 24, 362–368. [CrossRef]

11. Casale, T.B.; Teng, M.N.; Morano, J.P.; Unnasch, T.; Charles, J.; Lockwood, C.J. Zika virus: An emerging infectious disease with serious perinatal and neurologic complications. *J. Allergy Clin. Immunol.* 2018, 141, 482–490. [CrossRef] [PubMed]

12. Yang, Y.; Wong, G.; Ye, B.; Li, S.; Li, S.; Zheng, H.; Wang, Q.; Liang, M.; Gao, G.F.; Liu, L.; et al. Development of a reverse transcription quantitative polymerase chain reaction-based assay for broad coverage detection of African and Asian Zika virus lineages. *Virology*. 2017, 52, 39–43. [CrossRef] [PubMed]

13. Landry, M.L.; St George, K. Laboratory Diagnosis of Zika Virus Infection. *Arch. Pathol. Lab. Med.* 2017, 141, 60–67. [CrossRef] [PubMed]

14. Broeders, S.; Garlant, L.; Fridh, M.A.; Vandermassen, E.; Suin, V.; Vanhomwegen, J.; Dupont-Rouzyer, M.; Rousset, D.; Van Gucht, S.; Roosens, N. A new multiplex RT-qPCR method for the simultaneous detection and discrimination of Zika and chikungunya viruses. *Int. J. Infect. Dis.* 2020, 92, 160–170. [CrossRef] [PubMed]

15. Waggner, J.J.; Pinsky, B.A. Zika virus: Diagnostics for an emerging pandemic threat. *J. Clin. Microbiol.* 2016, 54, 860–867. [CrossRef] [PubMed]

16. Shukla, S.; Hong, S.Y.; Chung, S.H.; Kim, M. Rapid Detection Strategies for the Global Threat of Zika Virus: Current State, New Hypotheses, and Limitations. *Front. Microbiol.* 2016, 7, 1685. [CrossRef]

17. Lamb, L.E.; Bartolone, S.N.; Kutluay, S.B.; Robledo, D.; Porras, A.; Plata, M.; Chancellor, M.B. Advantage of urine based molecular diagnosis of Zika virus. *Int. Urol. Nephrol.* 2016, 48, 1961–1966. [CrossRef]

18. Munoz-Jordan, J.L. Diagnosis of Zika Virus Infections: Challenges and Opportunities. *J. Infect. Dis.* 2017, 216, S951–S956. [CrossRef] [PubMed]

19. Lee, H.J.; Kim, Y.B.; Shin, Y. Advances in Epidemiology, Biology and Laboratory Diagnosis of Zika Virus. *J. Bacteriol. Virol.* 2017, 47, 1–13. [CrossRef]

20. de Vasconcelos, Z.E.M.; Azevedo, R.C.; Thompson, N.; Gomes, L.; Guida, L.; Moreira, M.E.L. Challenges for molecular and serological ZIKV infection confirmation. *Childs Nerv. Syst.* 2018, 34, 79–84. [CrossRef]

21. Gourinat, A.C.; O’Connor, O.; Calvez, E.; Gourinat, A.C.; Million, P.; Bréard, M.; Vanhomwegen, J.; Billot, S.; Biron, A.; et al. Zika virus infection in New Caledonia and GuillaumBarre syndrome: A case-control study. *J. Neurovirol.* 2018, 24, 362–368. [CrossRef]

22. Lee, H.J.; Kim, Y.B.; Shin, Y. Advances in Epidemiology, Biology and Laboratory Diagnosis of Zika Virus. *J. Bacteriol. Virol.* 2017, 47, 1–13. [CrossRef]

23. de Vasconcelos, Z.E.M.; Azevedo, R.C.; Thompson, N.; Gomes, L.; Guida, L.; Moreira, M.E.L. Challenges for molecular and serological ZIKV infection confirmation. *Childs Nerv. Syst.* 2018, 34, 79–84. [CrossRef]

24. Qian, X.; Liu, H.; Zou, Q.; Yang, J.; Zheng, X.; Chen, Y.; Zhao, X.; Gao, G.F.; Li, Y.; et al. Prolonged detection of Zika virus RNA in urine samples during the ongoing Zika virus epidemic in Brazil. *J. Clin. Virol.* 2016, 77, 49–53. [CrossRef]

25. Cordeiro, M.T. Laboratory diagnosis of Zika virus. *Top. Magn. Reson. Imaging* 2019, 28, 15–17. [CrossRef]
27. Goertz, G.P.; Vogels, C.B.F.; Geertsema, C.; Koenraadt, C.J.M.; Pijlman, G.P. Mosquito co-infection with Zika and chikungunya virus allows simultaneous transmission without affecting vector competence of Aedes aegypti. *PloS Negl. Trop. Dis.* **2017**, *11*, e0005654. [CrossRef] [PubMed]

28. Brito, C.A.A.; Azevedo, F.; Cordeiro, M.T.; Marques, E.T.A., Jr.; Franca, R.F.O. Central and peripheral nervous system involvement caused by Zika and chikungunya coinfection. *PloS Negl. Trop. Dis.* **2017**, *11*, e0005583. [CrossRef] [PubMed]

29. Sardi, S.I.; Somasekar, S.; Naccache, S.N.; Bandeira, A.C.; Tauro, L.B.; Campos, G.S.; Chiu, C.Y. Coinfections of Zika and chikungunya viruses in Bahia, Brazil, identified by metagenomic next-generation sequencing. *J. Clin. Microbiol.* **2016**, *54*, 2348–2353. [CrossRef] [PubMed]

30. Zambrano, H.; Waggoner, J.J.; Almeida, C.; Rivera, L.; Benjamin, J.Q.; Pinsky, B.A. Zika Virus and Chikungunya Virus CoInfections: A Series of Three Cases from a Single Center in Ecuador. *Am. J. Trop. Med. Hyg.* **2016**, *95*, 894–896. [CrossRef]

31. Manual for the Laboratory Diagnosis of Measles and Rubella Virus Infection. Available online: https://www.malmed-oracol.co.uk/_webedit/uploaded-files/All%20Files/WHO%20instructions%20on%20processing%20Saliva%20samples.pdf (accessed on 1 April 2021).

32. Inizan, C.; Tarantola, A.; O’Connor, O.; Mangeas, M.; Pocquet, N.; Forfait, C.; Descloux, E.; Gourinat, A.-C.; Pfannstiel, A.; Klement-Frutos, E.; et al. Dengue in New Caledonia: Knowledge and Gaps. *Trop. Med. Infect. Dis.* **2019**, *4*, 95. [CrossRef]

33. Roth, A.; Mercier, A.; Lepers, C.; Hoy, D.; Duituturaga, S.; Benyon, E.; Guillaumot, L.; Souarès, Y. Concurrent outbreaks of dengue, chikungunya and Zika virus infections—An unprecedented epidemic wave of mosquito-borne viruses in the Pacific 2012–2014. *Euro Surveill.* **2014**, *19*, 20929. [CrossRef] [PubMed]

34. Del Pilar Martinez Viedma, M.; Puri, V.; Oldfield, L.M.; Shabman, R.S.; Tan, G.S.; Pickett, B.E. Optimization of qRT-PCR assay for zika virus detection in human serum and urine. *Virus Res.* **2019**, *263*, 173–178. [CrossRef] [PubMed]

35. Venceslau, E.M.; Guida, J.P.S.; Nobrega, G.D.M.; Samogim, A.P.; Parise, P.L.; Japecanga, R.R.; Toledo-Teixeira, D.A.D.; Forato, J.; Antolini-Tavares, A.; Souza, A.; et al. Adequate Placental Sampling for the Diagnosis and Characterization of Placental Infection by Zika Virus. *Front. Microbiol.* **2020**, *11*, 112. [CrossRef] [PubMed]

36. Fonseca, L.M.D.S.; Carvalho, R.H.; Bandeira, A.C.; Sardi, S.I.; Campos, G.S. Oropouche Virus Detection in Febrile Patients’ Saliva and Urine Samples in Salvador, Bahia, Brazil. *Jpn. J. Infect. Dis.* **2020**, *73*, 164–165. [CrossRef] [PubMed]